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Introduction: Chronic low back pain due to intervertebral disc (IVD) degeneration is associated with increased
levels of inflammatory mediators. Current medical treatment consists of oral anti-inflammatory drugs to alleviate
pain. In this study, the efficacy and safety of a novel thermoreversible poly-N-isopropylacrylamide MgFe-layered
double hydroxide (pNIPAAM MgFe-LDH) hydrogel was evaluated for intradiscal controlled delivery of the selective
cyclooxygenase (COX) 2 inhibitor and anti-inflammatory drug celecoxib (CXB).
Methods: Degradation, release behavior, and the ability of a CXB-loaded pNIPAAM MgFe-LDH hydrogel to suppress
prostaglandin E2 (PGE2) levels in a controlled manner in the presence of a proinflammatory stimulus (TNF-α) were
evaluated in vitro. Biocompatibility was evaluated histologically after subcutaneous injection in mice. Safety of
intradiscal application of the loaded and unloaded hydrogels was studied in a canine model of spontaneous mild
IVD degeneration by histological, biomolecular, and biochemical evaluation. After the hydrogel was shown to be
biocompatible and safe, an in vivo dose–response study was performed in order to determine safety and efficacy of
the pNIPAAM MgFe-LDH hydrogel for intradiscal controlled delivery of CXB.
Results: CXB release correlated to hydrogel degradation in vitro. Furthermore, controlled release from CXB-loaded
hydrogels was demonstrated to suppress PGE2 levels in the presence of TNF-α. The hydrogel was shown to exhibit
a good biocompatibility upon subcutaneous injection in mice. Upon intradiscal injection in a canine model, the
hydrogel exhibited excellent biocompatibility based on histological evaluation of the treated IVDs. Gene expression
and biochemical analyses supported the finding that no substantial negative effects of the hydrogel were observed.
Safety of application was further confirmed by the absence of clinical symptoms, IVD herniation or progression of
degeneration. Controlled release of CXB resulted in a nonsignificant maximal inhibition (approximately 35 %) of
PGE2 levels in the mildly degenerated canine IVDs.
Conclusions: In conclusion, this study showed biocompatibility and safe intradiscal application of an MgFe
LDH-pNIPAAM hydrogel. Controlled release of CXB resulted in only limited inhibition of PGE2 in this model
with mild IVD degeneration, and further studies should concentrate on application of controlled release from
this type of hydrogel in animal models with more severe IVD degeneration.* Correspondence: m.a.tryfonidou@uu.nl
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Chronic low back pain is a debilitating disorder associ-
ated with intervertebral disc (IVD) degeneration [1]. As
the exact pathogenesis is still poorly understood, current
surgical and medical treatments aim at alleviating symp-
toms. Inhibiting or reversing the degenerative process by
using advanced methods like cell and tissue engineering
are in development, but are not clinically applicable thus
far. In degenerative disc diseases, the specific compos-
ition of the nucleus pulposus (NP) and annulus fibrosus
(AF) is disturbed, since the delicate equilibrium shifts to-
ward the catabolic pathways [2, 3]. In the NP this results
in a change from an extracellular matrix (ECM) rich in
proteoglycans and type II collagen, to a tissue containing
mainly type I collagen, and in the AF in a loss of lamel-
lar organization [4, 5]. The loss of proteoglycans causes
a decrease in the water-binding capacity of the NP and
together with the changes in the AF, compromises the
structural functionality of the IVD [5].
A variety of inflammatory mediators has been investi-
gated for their role in the catabolic processes of IVD de-
generation; targeting the inflammation process is one of
the emerging treatment strategies of chronic low back
pain and IVD degeneration. Herniated degenerative disc
tissue has been shown to spontaneously produce in-
creased amounts of matrix metalloproteinases (MMPs),
nitric oxide, prostaglandin E2 (PGE2) and interleukin 6
(IL-6), and to express interleukin 1 (IL-1), interleukin 8
(IL-8), tumor necrosis factor alpha (TNF-α) [6, 7]. TNF-α
and IL-1 upregulate expression of matrix-degrading en-
zymes by NP cells [4, 8, 9]. Furthermore, elevated levels of
IL-1 and PGE2 have been associated with aging and de-
generation of the IVD [9, 10]. In the NP, PGE2 negatively
affects matrix integrity by inhibiting proteoglycan synthe-
sis, possibly mediated by a decrease in insulin growth fac-
tor 1 and an increase in matrix-degrading enzymes [10].
PGE2 is a well-known prostanoid and plays an import-
ant regulatory role in physiological as well as pathological
processes like intervertebral disc degeneration. It is syn-
thesized by two cyclooxygenase (COX) isoforms, COX-1
and COX-2, by conversion of arachidonic acid into prosta-
glandin H2 (PGH2) and isomerization of PGH2 to PGE2
by prostaglandin E synthases (PTGES). COX-1 is constitu-
tively expressed in most tissues and is associated with the
production of baseline PGE2 levels important for homeo-
stasis. In contrast, COX-2 expression is highly restricted
under physiological conditions, but can be rapidly induced
in response to inflammatory stimuli and is therefore be-
lieved to play an important role in the PGE2 production
involved in degenerative processes [11, 12]. Selective
COX-2 inhibitors have been developed to reduce PGE2
production via this pathway. In several clinical trials the ef-
ficacy of COX-2 inhibitors in patients with low back pain
has been established [13, 14]. However, their widespreadapplication is hampered by severe side effects, such as
cardiotoxicity. Although these inhibitors can be effectively
introduced into the avascular IVD by intradiscal injection,
they would achieve only short-lived clinical effects. De-
livering drugs by using controlled release systems, e.g.,
hydrogels, would be a more attractive alternative to bolus
injections, as a higher loading dose and long-term delivery
can be accomplished by a minimum of intradiscal inter-
ventions [15, 16].
Temperature-sensitive poly-N-isopropylacrylamide
(pNIPAAM)-based hydrogels have been extensively used
in the field of controlled release [17]. These gels could be
particularly suitable for intradiscal injection as they are li-
quid at room temperature, and hence injectable through
small-diameter needles and form a solid gel at 37 °C, pre-
venting leakage of injected materials from the IVD [18]. In
this study a hybrid thermoreversible biodegradable hydro-
gel served as a controlled release platform for the spe-
cific COX-2 inhibitor celecoxib (CXB). This release
system consists of lower critical solution temperature
(LCST) polymers with a low molecular weight, based on
pNIPAAM with a sulfonate end group, ionically linked to a
network of biodegradable platelet-type MgFe layered
double hydroxide (LDH) nanoparticles. LDH particles
possess a positive surface charge, which can interact
with the negatively charged LCST polymers. At room
temperature these hybrid structures are simply made by
mixing the polymer with the MgFe-LDHs and subsequent
dispersion in water. This results in a solution of low vis-
cosity that can easily be injected into the NP via a 29G
needle. At body temperature (37 °C), physical entangle-
ments are formed due to hydrophobic interactions be-
tween the LCST polymers, resulting in the formation of a
hybrid network, as polymers are linked to the MgFe-LDH
particles. Furthermore, the easily ionizable carboxylic
groups of CXB can interact with the biodegradable LDHs,
which makes this unique for drug release. We hypothesize
that pNIPAAM MgFe-LDH hydrogels are suitable vehicles
for delivering a COX-2 inhibitor into the IVD, to reduce
intradiscal PGE2 levels over time in a dog model with
spontaneous IVD degeneration, showing pathophysio-
logical aspects similar to those in human [19, 20].
Materials and methods
After synthesis, preparation, and rheological analysis of
the hydrogel, the degradation and release behavior of the
CXB-loaded hydrogel was evaluated. Furthermore, in an
in vitro model in the presence of a proinflammatory stimu-
lus (TNF-α) the ability of the CXB-loaded hydrogels to
suppress PGE2 levels in a sustained manner was evaluated.
Thereafter, biocompatibility upon subcutaneous injection
was studied in mice. Safety of intradiscal application of the
loaded and unloaded hydrogel was studied in a canine
model of spontaneous mild IVD degeneration. After the
Fig. 1 Rheological setup and results of the complex shear modulus
|G*| of the pNIPAAM MgFe-LDH hydrogel. a Configuration of the
rheological setup to measure |G*| of the pNIPAAM MgFe-LDH
hydrogel. b |G*| of the pNIPAAM MgFe-LDH hydrogel as a function
of temperature. The dashed red line connects the time point where
the |G*| starts to increase to the temperature curve, and indicates a
lower critical solution temperature (LCST) of 32 °C. AS after sterilization,
ASC after sterilization separate components, NS nonsterilized. G*
complex shear modulus, LDH layered double hydroxide, pNIPAAM
poly-N-isopropylacrylamide
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follow-up dose–response in vivo study was performed in
order to determine safety and efficacy of the pNIPAAM
MgFe-LDH hydrogel for intradiscal controlled delivery of
CXB.
Synthesis and preparation of pNIPAAM MgFe-LDH
hydrogels
The poly-N-isopropylacrylamide (pNIPAAM) polymer with
sulfonate end group was synthesized as reported previously
[21] and the modified synthesis is described in detail in
Additional file 1. To formulate the hydrogel, the pNIPAAM
polymer was added to the LDH suspension in a vial and
subsequently placed on a tube roller mixer for 48 h at room
temperature and sterilized by gamma radiation (25 kGy,
Isotron Nederland BV, Ede, The Netherlands). The final
hydrogel contained 16 wt % pNIPAAM, 3.3 wt % MgFe
LDH and water.
Rheological analysis of the pNIPAAM MgFe-LDH
hydrogels
The viscoelastic properties of the unloaded pNIPAAm
MgFe-LDHs were determined by using an Anton Paar
MCR301 rheometer (Anton Paar Ltd., St. Albans, UK) with
an oscillatory parallel plate geometry (50 mm diameter)
with a constant strain of γ = 0.5 % at a frequency of f = 1
Hz. Temperature was increased from 22 °C to 37 °C at a
rate of 15 °C/min. This heating rate was chosen based on
calculating the minimum rate of heat transfer based on
estimating the energy needed to heat up the hydrogel,
by taking into account the surface of the hydrogel and
the minimum temperature difference between the LCST
and body temperature. LCST is the critical temperature
above which the hydrogel undergoes a phase transition
from a soluble to an insoluble state. This estimation is
described in detail in Additional file 1. The gelling was
recorded by measuring the complex shear modulus |G*|,
which is a common parameter to determine the strength
of a viscoelastic material like a hydrogel. The complex
shear modulus |G*| is correlated to the storage modulus
(G’) and loss modulus (G”). The storage modulus is a
measure of the deformation energy stored in the sample
during the shear process (elastic behavior), whereas the
loss modulus is a measure of the energy dissipated in the
sample during the shear process (viscous behavior), and is
lost to the sample afterward (viscous behavior). The rela-
tion between these parameters is the following:
Gj j ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
G0ð Þ2 þ G}ð Þ2
q
Hydrogel samples were placed on the lower plate, and
the upper plate was lowered to a 0.5 mm gap. The con-
figuration of the rheological setup is shown in Fig. 1a.
The viscoelastic properties of the loaded hydrogel werenot determined. The CXB concentrations were as low as
10−6 M to 10−4 M, i.e., 0.38–38 mg of celecoxib per liter,
or 0.0038–3.8 × 10-5 wt %, and were not influencing the
rheological properties.
Degradation and release behavior of CXB-loaded pNIPAAM
MgFe-LDH hydrogels
In vitro, the controlled release of CXB from hydrogels
was measured in phosphate-buffered saline (PBS) (pH 7.4,
44 mM Na2HPO4, 9 mM NaH2PO4, 72 mM NaCl, 0.02 %
wt NaN3) and 0.2 % Tween 80® (polyoxyethylenesorbitan
monooleate; Sigma-Aldrich Chemie B.V., Zwijndrecht,
The Netherlands). Tween 80® was added to the buffer in
order to increase the solubility of CXB [22] and thereby simu-
late the in vivo situation. CXB-loaded pNIPAAMMgFe-LDH
suspension was prepared by adding 6 or 10 mg/ml of
CXB to the dispersion and stirring with a stirring bar
for 2 days. A volume of 1 ml of CXB-loaded pNIPAAM
MgFe-LDH suspension was pipetted into a vial and placed
for 30 min at 37 °C to ensure gelation of the hydrogel, and
afterward covered with 14 ml warm (37 °C) PBS/Tween
80® solution. The release experiment was performed at
37 °C. At day 1, 2, 5, 8, 15, 22, and 31, 12 ml of the buf-
fer solution was removed in order to analyze CXB and
Mg concentrations and 12 ml of fresh buffer was added.
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100 μl by using ultra-performance liquid chromatography
(UPLC) as described in detail recently by Petit et al. [23].
In vitro degradation was determined by measuring the
relative cumulative release of Mg into the medium. Mg
concentrations were determined by using a Prodigy High
Dispersion Inductively Coupled Optical Emission Specto-
metry (ICP-OES) system (Leeman Labs, St Charles, IL,
USA). Standards were prepared by using multi-element
(23 elements in diluted nitric acid) standard solution IV
(1000 mg/l) (Merck Millipore, Darmstadt, Germany). A
volume of 0.5 ml of the solutions from the degradation ex-
periment was diluted in 100 ml aqueous 1N HNO3, and
subsequently diluted again tenfold in 1N HNO3. The ef-
fects of CXB loading (10 mg/ml versus 6 mg/ml), LDH
content (single versus double) and type of LDH (Mg3Fe
versus Mg2.5Fe) of the gels on release behavior and
in vitro degradation were also investigated, as well as
CXB solubility effects by using a buffer containing PBS
and 0.2 % or 2 % Tween 80®.
Controlled release of CXB in vitro
The balance between anabolic and catabolic pathways in
articular chondrocytes as well as NP cells can be directed
toward catabolism by TNF-α [24, 25]. Bovine articular
chondrocytes were used in the in vitro experiments, as
they were more easily available in our laboratory. Articular
chondrocytes were isolated from bovine carpometacarpal
joints by enzymatic digestion overnight with 2 mg/ml
collagenase A (Roche Diagnostics Deutschland GmbH,
Mannheim, Germany) at 37 °C. Chondrocytes were seeded
at 5 × 106 cells/ml density (P0) into cylindrical (diameter
and height 6 mm) 2 % agarose (Type VII, Sigma-Aldrich
Chemie B.V.) constructs and left to gel at room
temperature. The constructs were then cultured in 12-well
plates in high-glucose Dulbecco’s modified Eagle’s medium
(hgDMEM; Gibco, Life Technologies Europe, Bleiswijk,
The Netherlands) with 20 % fetal bovine serum (Greiner
Bio-One, Alphen aan Den Rijn, The Netherlands), 0.1 %
amphotericin (Sigma-Aldrich Chemie B.V.), 1 % Pen-Strep
(Biochrom GmbH, Berlin, Germany), 1 % nonessential
amino acids (Lonza, Basel, Switzerland) 1 % essential
amino acids (Lonza), and 50 mg/ml ascorbate 2-phosphate
(Biochrom). During the first 5 days of culturing, these con-
structs were stimulated with 10 ng/ml TNF-α to induce an
inflammatory response reflected by elevated PGE2 levels
(Fig. 2a). A concentration of 1 μM CXB has been described
to effectively lower PGE2 levels in osteoarthritic chondro-
cytes and corresponds with mean pharmacological plasma
levels [26]. CXB was dispersed in the pNIPAAM MgFe-
LDH mixture at a concentration of 0.1 mg/ml, aiming to
establish a concentration of approximately 1 μM CXB per
culture medium renewal over the 28-day culture period.
Controlled release of the CXB is achieved by dissolution ofthe CXB crystals present a depot within the hydrogel and
diffusion of the solubilized CXB. A volume of 100 μl of
the hydrogel suspension was pipetted at the bottom of
a 12-well plate and placed in an incubator at 37 °C to
ensure gelation of the hydrogels. Subsequently, defined
as day 0 of the experiment, cell constructs and culture
medium were added to the 12-well plate. For the “bolus
injection” of CXB, only cell constructs were placed on
the bottom of the well, and CXB was added to the medium
every 2 days, starting at day 0, at a concentration of 1 μM.
Media were renewed every 2–3 days, collected on days 0,
2, 7, 9, 11, 14, 21, and 28 and stored at −80 °C for analysis
of CXB content. For the in vivo experiments based on for-
mulation of higher doses of CXB, in vitro experiments
were also carried out with a higher dosage of CXB to
evaluate release profiles at higher dosing. To this end, 1
mg of CXB-loaded per ml of hydrogel, aiming to establish
a concentration of 10 μM CXB per culture medium re-
newal was used. Conditioned media were analyzed for
CXB content and PGE2 levels. Inhibition of COX-2 ac-
tivity was determined by measuring PGE2 in culture
medium. A colorimetric competitive enzyme immuno-
assay kit (PGE2 EIA kit, Enzo Life Sciences BVBA,
Antwerp, Belgium) was used to determine PGE2 levels
in culture medium according to the manufacturer’s
instructions.
In vivo biocompatibility in mice after subcutaneous
implantation
All animal procedures were approved and performed in
accordance with the guidelines set by the Animal Experi-
ments Committee (DEC) of Utrecht University (experi-
ment numbers: DEC 2010.III.03.046; DEC 2012.III.05.046;
and DEC 2013.III.02.017). Six healthy female adult (8–10
weeks old) BALB/c mice (Harlan-Olac Ltd., Bicester, UK)
were used for testing biocompatibility and biosafety of the
pNIPAAM MgFe-LDH polymer hydrogel and seven other
biomaterials. Four different biomaterials were injected
at least 1 cm apart from each other into the dorsal sub-
cutaneous tissue of each mouse in a randomized fashion.
Buprenorphine 100 μg/kg was given intraperitoneally (i.p.)
as premedication and analgesic and subsequently all ani-
mals were anesthetized with isoflurane via an induction
mask (vaporizer setting 2.5 %) in a 1:1 oxygen:air mixture.
A blood sample was drawn to perform a white blood cell
count and differentiation at day 0, to rule out systemic in-
flammation. A volume of 200 μl of each biomaterial was
injected subcutaneously with a 27G needle under sterile
conditions. PBS (200 μl) served as a control. All injection
sites were marked with a waterproof marker. Immediately
after injection, Dermabond® (Ethicon, Cornelia, GA, USA)
was applied to the injection site to prevent leakage
and the injection site was heated by an infrared lamp
for 1 min. Mice were monitored daily for signs of distress
Fig. 2 In vitro controlled release of CXB results into sustained suppression of PGE2 levels in the presence of a proinflammatory stimulus. a Experimental
setup to evaluate the controlled release of celecoxib (CXB) in vitro. During the first 5 days of culturing, three-dimensional chondrocyte constructs were
stimulated with a proinflammatory cytokine TNF-α (10 ng/ml). At day 0 of the experiment, a 10 μM bolus injection of CXB was applied for 2 consecutive
days or pNIPAAM MgFe-LDH hydrogels loaded with 1 mg/ml CXB (CR CXB). Media were refreshed every 2–3 days and collected on days 0, 2, 7, 9, 11, 14,
21, and 28. On days 14 and 28 the constructs were evaluated for cell viability. b Celecoxib (CXB) concentrations (μM) were measured in medium samples
after administering the bolus injection of CXB or the pNIPAAM MgFe-LDH hydrogel loaded with 1 mg/ml CXB (CR CXB) c. PGE2 concentrations (ng/ml)
measured in medium samples in the following conditions: unstimulated, stimulated with 10 ng/ml TNF-α (TNF-α stimulated), TNF-α stimulated
in the presence of a 10 μM bolus injection of celecoxib (CXB bolus) for 2 consecutive days, or 1 mg/ml CXB-loaded pNIPAAM MgFe-LDH
hydrogels (CR + CXB). Data are expressed as mean ± standard deviation. CR control, LDH layered double hydroxide, PGE2, prostaglandin E2,
pNIPAAM poly-N-isopropylacrylamide, TNF-α tumor necrosis factor alpha
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abnormal posture) and injection sites were monitored
for inflammation (e.g., swelling, redness, pain, and heat).
Three animals were sacrificed 7 days after injection, and
three after 28 days. At the end of the experimental period,
animals were anesthetized with isoflurane, blood was col-
lected by cardiac puncture for white blood cell count and
differentiation, and euthanasia was performed by cervical
dislocation. The injection sites were removed for histo-
logical analysis. Tissues were fixated in a 4 % neutral-
buffered formaldehyde solution (Klinipath B.V., Duiven,
The Netherlands) and after fixation routinely embedded
in paraffin. Sections of 4 μm were stained with hematoxylin
and eosin. Infiltration of inflammatory cells, giant cells,
necrosis, neovascularization, fatty infiltration, and the
encapsulation of the biomaterial by a fibrotic capsule
were histologically assessed as parameters for a bio-
logical response at the application site, at 7 and 28 days
by a blinded board-certified veterinary pathologist (GG)
and the principal investigator (NW) using an Olympus
BX41 microscope (Olympus Europa GmbH, Hamburg,
Germany).Intradiscal application of CXB-loaded pNIPAAM MgFe-LDH
hydrogels in laboratory beagle dogs
Data from two in vivo studies in beagle dogs were com-
bined and analyzed. Both studies were set up as random-
ized block designs. In the first study CXB-loaded (7.7 μM)
and unloaded pNIPAAM MgFe-LDH hydrogels, a bolus
injection of CXB (7.7 μM) and 0.9 % NaCl were intradis-
cally injected. In other levels two other materials irrelevant
to this study were injected. The second study served as a
dose–response study, including a 10- and 100-fold higher
dosage of CXB (77 μM and 770 μM) in addition to the
7.7 μM dose. For preparation of the CXB-loaded hydro-
gels, CXB was prepared from a CXB stock solution in
ethanol (60 μg/ml) by sterile filtration. Water was added
to this ethanolic solution of CXB to obtain a dispersion
with small CXB crystals (diameter approximately 1 μm).
This dispersion was freeze-dried overnight and the
pNIPAAM MgFe-LDH mixture was added and incubated
overnight on a tube roller mixer at room temperature.
In total 18 intact female beagle dogs (Harlan, Gannat,
France) with a median age of 1.7 years (range 1.3–1.8
years) and a median weight of 8.4 kg (range 6.2–13.8 kg)
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(range 1.3–1.8 years) and a median weight of 8.2 kg
(range 6.2–11 kg) were used in the first study. Nine dogs
with a median age of 1.7 years (range 1.6–1.8 years) and
a median weight of 9.3 kg (range 8.3–13.8 kg) were used
in the second study. All dogs underwent general, ortho-
pedic, and neurologic examination by a board-certified
veterinary surgeon (BM).
Surgical procedure
To determine the grade of degeneration of the IVDs
prior to surgery, magnetic resonance (MR) images of the
lumbar vertebral column were obtained in fully anesthe-
tized dogs. A blood sample was drawn from the jugular
vein to assess white blood cell count and differentiation,
to exclude systemic inflammation. Dogs were placed in a
dorsal recumbent position and throughout the complete
scan protocol heart rate, respiration rate, temperature, car-
bon dioxide, and oxygen levels were monitored. The MR
imaging was performed using a 0.2 Tesla open magnet
(Magnetom Open Viva, Siemens AG, Munich, Germany).
All lumbar IVDs were assessed according to the Pfirrmann
score by a veterinary radiologist on sagittal T2-weighted
fast spin echo (FSE) images (3.0 mm slices, repetition time
(TR) 4455 ms, echo time (TE) 117 ms) [27]. Only lumbar
IVDs with a Pfirrmann score II were included for injection.
The anesthesia protocol during surgery was similar
to the one used during MR scanning. Analgesia was
provided by a combination of fentanyl (loading dose
10 μg/kg, 15–20 μg/kg/h continuous rate infusion, c.r.i.)
and ketamine (0.5 mg/kg loading dose, 10 μg/kg/min
c.r.i.) intravenous (i.v.). Throughout the complete pro-
cedure heart rate, respiration, temperature, carbon di-
oxide, oxygen levels, and blood pressure (noninvasive)
were monitored. Surgical sites were prepared according
to standard protocol. A detailed description of the surgical
procedure has been described previously [28]. Briefly, dogs
were positioned in a right recumbent position to expose
and inject the T13-L1 until L6-L7 via a left lateral ap-
proach. To diminish injury of the iliopsoas muscle and sci-
atic nerve traction injury, the surgical approach in the
second study was adjusted and L6-L7 and L7-S1 were
injected via a dorsal approach, while the dogs were posi-
tioned in ventral recumbency. In the first study a 100 μl
syringe (7638–01 Model 710 RN, Hamilton Company
USA, Reno, NV, USA), and in the second study a 100 μl
gastight syringe (7656–01 Model 1710 RN) with a 29G
needle (25 mm, 12° beveled point; Hamilton Company
USA) was used to inject 30 μl of the earlier mentioned
compounds through the AF into the NP. The smallest
possible needle diameter was chosen to minimize injury
to the treated IVDs. Wound closure was performed ac-
cording to standard protocol. Postoperative pain man-
agement in all dogs consisted of methadone 0.3 mg/kgintramuscular (i.m.) quaque (q).6.h. during the first 24 h
postoperatively and buprenorphine 20 μg/kg i.m. q.4.h.
and/or tramadol 2–5 mg/kg per os (p.o.) q.6.h. the follow-
ing 7 days. All dogs were treated postoperatively with anti-
biotics (amoxicillin/clavulanic acid 12.5 mg/kg q.12.h p.o.)
during 5 days. Dogs were monitored daily throughout the
study by a veterinarian to assess pain symptoms according
to the short form of the Glasgow composite pain scale.
Dogs that showed signs of pain, received tramadol and/or
buprenorphine and/or gabapentin (5 mg/kg p.o. q.12.h).
Furthermore, animals were monitored daily by a veter-
inarian for clinical signs of illness, neurologic deficits
and lameness.
Injected substances
In the first study spontaneously degenerated IVDs (Pfirmann
grade 2) of the dogs were injected with a volume of
30 μl of NaCl 0.9 % (sham), a bolus of CXB (7.7 μM),
a CXB-loaded (7.7 μM) and an unloaded pNIPAAM
MgFe-LDH hydrogel. Based on studies in cadaveric
spines (unpublished data, N. Willems, and B.P. Meij)
a volume of 30 μl could be injected into the NP without
substantial resistance. The volume of 30 μl contained
7.7 μM × 10−6 M CXB, to achieve a final concentration
of 1 μM (=7.7 × 10−6 × (30 μl gel/230 μl NP volume
plus gel)) for the bolus of CXB, in the canine NP of
beagle laboratory dogs with a mean weight of 8–9 kg and
taking into account the volume of the nucleus (200 μl)
[29]. All substances were injected into the IVDs in the
T12-L6 spinal segment in a randomized fashion, except
for the sham treatment (NaCl 0.9 %), which was
injected into T12-T13. An interim statistical analysis
was performed after the first study to evaluate treat-
ments and study design. Results were used to perform a
new power analysis and to adapt the study design of
the second study. In the second study, all substances
were administered in a random order within each ani-
mal and IVDs of the T12-S1 spinal segment were
injected with NaCl 0.9 %, a bolus of CXB (7.7 μM),
CXB-loaded (7.7 μM, 77 μM and 770 μM) hydrogels,
and an unloaded pNIPAAM MgFe-LDH hydrogel. IVDs
adjacent to those injected with hydrogel loaded with
the highest dose of CXB (770 μM) remained untreated.
Postmortem collection of materials
Dogs were euthanized 4 weeks postinjection. First, they
were sedated with dexmedetomidine 0.04 mg/kg i.v.,
followed by pentobarbital 200 mg/kg i.v. Immediately
after euthanasia, the vertebral column (T12-S1) was
harvested by using an electric multipurpose saw (Bosch,
Stuttgart, Germany). All muscles were removed and the
vertebrae were transected transversely with a band saw
(EXAKT tape saw, EXAKT Advanced Technologies
GmbH, Norderstedt, Germany), resulting in nine spinal
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transected sagittally by using a diamond band pathology
saw (EXAKT 312 saw; EXAKT diamond cutting band
0.1 mm D64; EXAKT Advanced Technologies GmbH),
generating two identical parts. One half was resected with
a surgical knife by removing the endplate and the vertebra
attached to it on one side, and the remaining IVD tissue
was snap frozen in liquid nitrogen stored at −80 °C for
biochemical and biomolecular analyses. The other half
was photographed (Olympus VR-340, Olympus Europa
GmbH) for macroscopic evaluation of the IVD (Thompson
score, see below) and stored for 14 days in 50 ml of 4 %
buffered formaldehyde at 4 °C for histological analyses.
Histology, COX-2 immunohistochemistry, and TUNEL assay
Samples were decalcified in 35 % formic acid and 6.8 %
sodium formate in a microwave oven (Milestone Microwave
Laboratory Systems, Bergamo, Italy) overnight at 37 °C, for
7 nights [30] and embedded in paraffin. Five-μm-thick
sections were stained with hematoxylin and eosin and
with picrosirius red/alcian blue and evaluated according
to a grading scheme according to Bergknut et al. [31].
Histological slides were scored blinded and in random
order by two independent investigators (NW, AT) using
an Olympus BX41 microscope (Olympus Europa GmbH).
In case of doubt, samples were also scored by a board-
certified veterinary pathologist (GG). All photographs of
the macroscopy of the IVD segments were evaluated by
two independent blinded investigators (NW, AT) ac-
cording to the Thompson grading scheme, which has
been validated in dogs [32].
Immunohistochemistry for COX-2 was performed on
5 μm sections mounted on KP-plus glass slides. After
deparaffinization and rehydration, sections were treated
with Dual Endogenous Enzyme Block (Dako S2003, Dako,
Carpinteria, CA, USA) for 10 min at room temperature to
block nonspecific endogenous peroxidase, followed by two
washing steps each of 5 min with Tris-buffered saline with
1 % Tween 20® (TBST). Sections were treated with
Tris-buffered saline (TBS) bovine serum albumin (BSA)
5 % solution to block nonspecific binding for 60 min at
room temperature, were carefully rinsed and subsequently
incubated with a primary mouse anti-human monoclonal
COX-2 antibody (Cayman Chemical, Ann Arbor, MI, USA)
diluted 1:50 in TBS-BSA 5 % overnight at 4 °C. The follow-
ing day sections were incubated with peroxidase-labeled
polymer (Envision™ anti-mouse K4001, Dako). Antibody
binding was visualized by using diaminobenzidine (DAB;
Dako). Sections were counterstained with hematoxylin
solution (Hematoxylin QS, Vector Laboratories Ltd.,
Peterborough, UK) and mounted in permanent mount-
ing medium.
A commercial available terminal deoxynucleotidyl trans-
ferase dUTP nick-end labeling (TUNEL; Merck Millipore,Darmstadt, Germany) assay was used according to the
manufacturer’s instructions to determine apoptosis.
The percentage of COX-2-positive and TUNEL-positive
chondrocytes over the total number of cells was deter-
mined by manual counting in the NP, and in the ventral
(VAF) and dorsal AF (DAF), by two blinded independ-
ent investigators (NW, SP).
Biomolecular and biochemical analyses
Cryosections (60 μm) of the spinal units were cut with a
cryostat (Leica CM1800 cryostat, Leica Microsystems
Inc., Bannockburn, IL, USA) and collected on RNAse-free
glass slides. The NP and AF tissues were separated and
half of the slides were collected in respectively 400 μl
and 750 μl Ambion® KDalert™ lysis buffer solution (Life
Technologies) in the first study, and in Complete Lysis-M
EDTA-free buffer (Roche Diagnostics Nederland B.V.,
Almere, The Netherlands) in the second study and stored
at −80 °C until biochemical analyses were performed. The
other half was collected in 300 μl RLT buffer containing
1 % β-mercaptoethanol (Qiagen, Venlo, The Netherlands)
and stored at −80 °C until biomolecular analyses were
performed.
Quantitative PCR (qPCR) was performed to assess the
effects of (controlled release of ) CXB at gene expression
levels of the NP with regards to: 1) ECM anabolism: aggre-
can (ACAN), collagen type II (COL2A1), collagen type I
(COL1A1); 2) ECM catabolism: a disintegrin and metallo-
proteinase with thrombospondin motifs 5 (ADAMTS5),
matrix metalloproteinase 13 (MMP13), tissue inhibitor
of metalloproteinase 1 (TIMP1); 3) inflammation: tumor
necrosis factor alpha (TNFA), interleukin-1β (IL1B),
interleukin-6 (IL6) and interleukin-10 (IL10); 4) COX
pathway and PGE2 synthesis: prostaglandin E synthase
1 (PTGES1), prostaglandin E synthase 2 (PTGES2), cy-
clooxygenase 1 (COX1), and cyclooxygenase 2 (COX2);
5) notochordal markers: brachyury (T), cytokeratin-8
(CK8), cytokeratin-18 (CK18); 6) the indirect effect of
CXB on Wnt signaling pathway: axin-2 (AXIN2), c-Myc
(c-Myc) and cyclin-D1 (CCND1) and 7) apoptosis:
caveolin-1 (CAV1), caspase 3 (CASP3), fas ligand (FasL)
and Bcl-2 (BCL2). The primer pairs used for qPCR are
given in Additional file 2.
The RNeasy Fibrous Tissue Mini Kit (Qiagen, Venlo, The
Netherlands) was used to isolate total RNA. To maximize
RNA yield, the incubation period with proteinase K was
reduced to 5 min. After on-column DNase-I digestion
(Qiagen RNase-free DNase kit) RNA was quantified by
using a NanoDrop 1000 spectrophotometer (Isogen Life
Science B.V., Ijsselstein, The Netherlands). cDNA was
synthesized from 20 ng total RNA in a total volume of
15 μl using the iScript™ cDNA Synthesis Kit (Bio-Rad
Laboratories B.V., Veenendaal, The Netherlands). qPCR
was performed in duplicate using an iCycler CFX384
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(Bio-Rad Laboratories). All dog-specific primers were
designed in-house using Perlprimer [33] except forMMP13
[34]. Primer specificity was evaluated with BLAST, and
the designed amplicon was tested for secondary struc-
tures using MFold [35]. Primers were purchased from
Eurogentec, Maastricht, The Netherlands. Amplification
efficiencies ranged from 80 to 115 %. Relative expression
levels were determined by normalizing the cycle threshold
(Ct) value of each target gene by the mean Ct value of
three reference genes, i.e., glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), ribosomal protein S19 (RPS19),
and TATA-binding protein (TBP).
To measure glycosaminoglycan (GAG) and DNA con-
tent in the NP and AF, samples in Ambion® KDalert™
lysis buffer solution were homogenized in a tube rotator
O/N at 4 °C, whereas samples in Complete Lysis-M
EDTA-free buffer were homogenized in a TissueLyser
II (Qiagen) for 2 × 30 s at 20 Hz. The supernatant and
pellet of each NP and AF were digested overnight in a
papain buffer (250 μg/ml papain (Sigma-Aldrich) in 50 mM
EDTA and 5 mM L-cysteine) at 60 °C. GAG content was
quantified by using a 1,9-dimethylmethylene blue assay
[36]. The Quant-iT™ dsDNA Broad-Range assay kit in com-
bination with a Qubit™ fluorometer (Invitrogen, Carlsbad,
CA, USA) was used in accordance with the manufacturer’s
instructions to determine DNA content in the papain-
digested NP and AF supernatant and pellets. DNA con-
tent in the supernatants of the NP and AF were negligible
and therefore not included in the total content.
PGE2 levels were measured with the same colorimetric
competitive enzyme immunoassay kit (PGE2 high sensi-
tivity EIA kit, Enzo Life Sciences BVBA) that was used
for the in vitro experiments. Both buffers that were used
to lyse tissue were validated and standards were diluted
in the same lysis buffer as the samples, which did not show
strong interference with the performance of the kit. Total
GAG content and PGE2 levels were normalized for DNA
content in the pellet and were measured in the NP as well
as the AF.
Statistical analyses
Power analyses were performed prior to both in vivo
studies by using free software [51], and are described in
detail in Additional file 3. PGE2/DNA in the NP was con-
sidered to be the main read-out parameter. Biochemical
and biomolecular data were analyzed by using the R statis-
tical software, package 2.15.2. A linear mixed-effects
model was used to analyze the effect of the injected treat-
ments. Factors incorporated into the model as a fixed
effect were ‘treatment’ (NaCl, CXB 7.7 μM, CR, CR +
7.7 μM, CR + 77 μM, CR + 770 μM), ‘tissue’ (NP and AF),
and their interaction. Random effects ‘dog’ (dog 1–18)
and ‘study’ (study 1 and 2) were incorporated to capturethe correlation between multiple measurements within
one dog. Residual plots and quantile–quantile (QQ)-plots
were used to check for possible violations of normality as-
sumptions. In case of violation, data were logarithmically
transformed. The Cox proportional hazards regression
model was used to estimate the effect of the injected treat-
ments on gene expression levels. Calculations were per-
formed on Ct values for each target gene and the mean Ct
value of three reference genes was incorporated into the
model as a covariate. If proportional hazard assumptions
were violated, the ratio of the Ct values for each target
gene to the mean Ct value of the reference genes was used
for analysis. Ct values ≥ 40 were right censored. Regression
coefficients were estimated by the maximum likelihood
method. Model selection was based on the lowest Akaike
information criterion (AIC). Confidence intervals were
calculated and stated at the 99 % confidence level to correct
for multiple comparisons. Differences between treatments
were considered significant if the confidence interval did
not include 0, whereas hazard ratios were considered
significant if the confidence interval did not include 1.
Results
Rheological properties and handling of the pNIPAAM
MgFe-LDH hydrogels
At low temperatures (22 °C) the complex modulus |G*| =
10 Pa and at high temperatures (37 °C) the complex
modulus |G*| = 2 kPa. Typical mechanical properties of a
NP are in the range of 7–21 kPa [38, 39]. However, this
hydrogel was not intended to be used as a replacement for
the NP and therefore no load-bearing properties were
needed. The slightly lower modulus of the hydrogel was
sufficient for the purpose of controlled drug release, and
for the intradiscal injection of a small volume, without in-
creasing intradiscal pressure with inherent effects on
homeostasis of the resident cells. Sterilization with gamma
radiation did not have a significant effect on the rheo-
logical properties of the gel (Fig. 1b). The viscous hydrogel
transitioned from a low-viscous state to a stable hydrogel
state within 10 s due to the hydrophobic interactions
between the isopropyl groups of pNIPAAM upon
increasing the temperature above its lower critical solu-
tion temperature (LCST) 32 °C (Fig. 3a and 3b). The low
viscosity solution could easily be injected at room
temperature via a 29G needle.
Degradation and controlled release of CXB from pNIPAAM
MgFe-LDH hydrogels in vitro
A cumulative release of 14 % CXB from hydrogels
loaded with 10 mg/ml CXB was shown after 31 days,
whereas a cumulative release of 11 % Mg was detected,
the former indicating that CXB is still present in the
hydrogel and controlled release of CXB is most probably
accomplished over more than 31 days. The release of
Fig. 3 a Schematic diagram of the formation of stable hybrid hydrogels. Positively charged layered double hydroxides (LDH) in a pNIPAAM solution
(pNIPAAM chain) transit from a low-viscous state to a stable hydrogel due to hydrophobic interactions between the isopropyl groups of pNIPAAM
upon increasing temperature. The celecoxib (CXB) is present in the hydrogel in small crystals, forming a depot, from which dissolution and diffusion
takes place. b At 37 °C gelation occurs within 10 s. c One month after intradiscal injection the pNIPAAM MgFe-LDH hydrogel (white arrow)
is visible in the nucleus pulposus (NP; **). The annulus fibrosus (AF) is indicated with a black arrow. LDH layered double hydroxide, pNIPAAM
poly-N-isopropylacrylamide
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LDH particles in PBS/0.2 % Tween® (Additional file 1).
An increase in the concentration of Tween® is known
to accelerate gel degradation and increase CXB solubility
and resulted in a threefold higher Mg release and a two-
to threefold higher release of CXB (Additional file 1) [22].
Neither an increase in the amount of LDH particles, nor
the charge of Mg affected the CXB release profile. Fur-
thermore, a 1.5-fold increase in the cumulative release of
CXB could be detected in gels with a 6 mg/ml loading
dose of CXB compared with a 10 mg/ml loading dose.
However, the absolute amount of CXB was comparable
(20 % of 10 mg/ml versus 30 % of 6 mg/ml) (Additional
file 1). Hydrogels with higher amounts of LDH parti-
cles showed a lower amount of cumulative Mg release
(Additional file 1). Degradation of pNIPAAM MgFe-LDH
hydrogels and controlled release of CXB in vitro are illus-
trated in the figures depicted in Additional file 1.
Agarose–cell constructs incubated with 10 μM CXB
bolus for 2 consecutive days apparently had taken up
CXB by diffusion, leading to detectable amounts of CXB
in the medium up to 7 days, which then dropped to zero
(Fig. 2b). CXB released from the 0.1 mg/ml loaded hydro-
gels into the culture medium ranged from 1.1 to 4.2 μM
(Additional file 1). CXB released from hydrogels loaded
with 1 mg/ml CXB resulted in CXB concentrations in the
medium ranging from 3 to 15.9 μM. To determine the ac-
tivity of the released CXB, cells in the constructs were
stimulated by 10 ng/ml TNF-α, which resulted indetectable PGE2 levels in the culture medium at day 9.
Application of the 10 μM bolus of CXB during 2 consecu-
tive days resulted in suppression of PGE2 levels from day
9 to 11, and PGE2 levels started to increase afterward to
similar levels as the TNF-α-stimulated constructs. In the
constructs cultured in the presence of 1 mg/ml CXB-
loaded hydrogels, TNF-α-induced PGE2 production was
completely inhibited throughout the whole culture period
of 28 days (Fig. 2c).In vivo biocompatibility in mice
Subcutaneous injection of the different hydrogels showed
no adverse local or systemic effects. At 7 days postinjec-
tion a fibrous capsule of varying thickness (57–76 μm)
was present in all hydrogel-injected tissue samples. At the
interface between the hydrogel and this capsule mainly
neutrophils and macrophages were present, consistent
with an acute/subacute pyogranulomatous reaction (Fig. 4).
At 28 days postinjection the hydrogel and fibrous capsules
were also present. In two samples a decreased thickness
of the fibrotic capsules (35 and 40 μm) was observed,
whereas in one sample a thickened capsule (236 μm) was
observed. In all three samples macrophages constituted
the predominant cell type in the intermediate layer, con-
sistent with a granulomatous reaction. Some of these mac-
rophages showed marked evidence of phagocytic activity.
In two samples injected with PBS (control), a slight in-
crease in macrophages was seen at day 28 compared with
Fig. 4 Representative histological images of subcutaneous injection sites in mice (hematoxylin and eosin stain). a-c show the skin and subcutis
of a control animal at 7 days revealing the epidermis (arrow a), hair follicles (arrowhead a) and striated muscle (panniculus carnosus; asterisk a
and b). The panniculus carnosus (asterisk c) and an occasional mastcell (arrowhead c) are visible in the subcutis. d-f show the skin 7 days after injection
of the hydrogel. The hydrogel is visible as a grey, granular substance (white arrow e) positioned below the panniculus carnosus (arrowhead e)
surrounded by a capsule of loosely arranged fibroblasts (asterisk e). Multifocally infiltrates of eosinophils (white arrow f), neutrophils (arrowhead f) and
macrophages (black arrow f) separating the hydrogel from the fibrous capsule. g-i show the skin of a control animal at 28 days after injection without
significant pathological changes. j-l depict the histological changes in the subcutis 28 days after injection of the hydrogel with the epidermis and
panniculus carnosus indicated by an arrow and arrowhead respectively in j. k shows a more compact fibrous capsule (arrow) compared to the loose
capsule seen after 7 days postinjection. The cellular reaction directly surrounding the hydrogel show a more granulomatous nature indicated by the
presence of macrophages often containing brown pigment l
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infiltration were not observed at either time point.
Intradiscal application and controlled release of CXB-
loaded hydrogels in laboratory beagle dogs
Surgical follow-up
Before surgery a total of 162 IVDs were graded on MR
images. A total of 9/162 IVDs were assigned a grade I
according to the Pfirmann system, whereas 153/162 IVDs
were assigned a grade II, of which 88 were injected in this
study. Six out of nine dogs in the first study were ambu-
lant the day after the injections of the test substances in
the IVD and showed a slight reduction in spinal reflexes
that recovered within the following 7 days. Three dogs
also showed reduced weight bearing of the left hind limb,
and received pain medication for a longer period of time.
Two dogs that received pain medication for 7 more days,
recovered completely. In one of these dogs slight dehis-
cence of the wound was detected and antibiotics were
given for a total of 14 days. In one dog the reduction in
spinal reflexes and weight bearing of the left hind limb
persisted and this dog was also treated with gabapentin 5
mg/kg p.o. q.12.h. All dogs in the second study showed
uneventful recovery from surgery, were ambulant the
next day and showed minor reductions in spinal reflexes
that recovered within 7 days.
IVD integrity
Postmortem, Thompson score grade II was assigned to
87/88 IVDs; a grade III was assigned to 1/88 IVDs,
which had been injected with the unloaded hydrogel. In
17/52 IVDs injected with the hydrogel, the tan-colored
hydrogel was visible in the mid-sagittal sections of the
NP (Fig. 3c). Histological evaluation of the total of 88
IVDs was performed as per the grading scheme accord-
ing to Bergknut et al. [31]. Scores ranged from 4 to 14.
The median histological grade in the first study was 9.5
(4–13) and in the second study 11 (8–14). No significant
differences were found between the injected treatments.
In one of the IVDs injected with the empty hydrogel
(level L6-L7), fibrotic tissue was present in the dorsal
AF; in another IVD injected with the empty hydrogel
(level L7-S1), the central parts of both sides of the end-
plates (EPs) were very irregular and clusters of chondro-
cytes were present in the dorsal AF at both sides of the
AF-EP interface. In one of the IVDs injected with NaCl
(level T12-T13), acellular material was detected in the
ventral AF. At macroscopic examination slight bulging
of the ventral AF was noticed.
Relative gene expression levels of BCL2, a regulatory
gene of cell death (apoptosis) were significantly down-
regulated in the CXB-loaded hydrogel compared with the
sham (HR = 8.28, CI 99 % 1.45–47.19) (Fig. 5a). However,
gene expression levels of other apoptotic markers, i.e.,CAV1, CASP3, and FasL showed no signs of increased
apoptosis in any of the treatments. Percentages of
TUNEL-positive cells per total cell count showed no
differences between treatments either (median 0 %,
range 0–82 %). Furthermore, there were no significant
differences in gene expression levels of notochordal cell
markers T, CK8, CK18, nor in levels of AXIN2, c-Myc,
and CCND1, associated with the Wnt pathway between
the treatments.Extracellular matrix metabolism
Relative gene expression of the catabolic gene ADAMTS5
was significantly upregulated in the NP samples treated
with the CXB bolus (HR = 10.35, CI 99 % 1.74–61.57) and
the CXB-loaded hydrogel (HR = 10.66, CI 99 % 1.70–
66.67) (Fig. 5b) compared with the unloaded hydrogel.
Gene expression levels of other catabolic (MMP13) and
anti-catabolic (TIMP1) genes were not significantly dif-
ferent between treatments (Fig. 5b). However, genes as-
sociated with extracellular matrix (ECM) components,
i.e., ACAN, COL2A1, COL1A1 did not significantly dif-
fer between treatments (Fig. 5c). These findings were
consistent with normalized GAG content (GAG/DNA)
in the NP as well as the AF, which did not significantly
differ between treatments 4 weeks postinjection. GAG/
DNA levels were significantly higher in the NP than in
the AF in all treatments (M = 0.58, SD = 0.03, CI 99 %
0.50–0.66) (Fig. 6b).COX pathway and PGE2 levels
In all CXB-loaded hydrogels, a decrease in PGE2/DNA
levels in the NP was detected relative to the NaCl-
injected NPs, with a maximum reduction of 35 % for the
77 μM CXB-loaded hydrogel. However, PGE2/DNA levels
in the NP as well as the AF showed high standard devi-
ations and were not significantly different between the
treatments 4 weeks postinjection. Gene expression levels
of genes involved in PGE2 biosynthesis, i.e., PTGES1,
PTGES2, COX1, and COX2, showed no significant dif-
ferences between treatments either. Relative gene expres-
sion levels of genes associated with inflammation, i.e.,
TNFA, IL1B, IL6, and IL10 were below the detection level
for all conditions. Cells expressing positive immunohisto-
chemical COX-2 staining were detected in only three sites
out of a total of 162 (54 IVD levels), Percentages of COX-
2-positive cells in the NP and VAF of two IVDs injected
with 770 μM CXB-loaded hydrogel were low, 0.5 % and
2 % respectively, and 0.6 % in an IVD injected with
unloaded hydrogel. Regardless of the treatment, PGE2/
DNA levels in the NP were significantly lower than those
detected in the AF (M = −0.64, SD = 0.08, CI 99 % −0.85
to −0.43) (Fig. 6c).
Fig. 5 a-c. Relative gene expression levels per treatment. The NaCl (sham) treatment in nucleus pulposus (NP) tissue is set at 1. a Relative gene
expression levels of ADAMTS5 were significantly upregulated in the NP samples treated with the celecoxib (CXB) bolus (CXB 7.7 μM) and the
CXB-loaded hydrogel (CR + CXB 7.7 μM) compared with the unloaded hydrogel (CR). b Gene expression levels ACAN, COL2A1, COL1A1 did not
significantly differ between treatments. c BCL2 expression levels were significantly downregulated in the CXB-loaded hydrogel compared with
the sham (NaCl). Data are expressed as n-fold changes ± standard deviation. d and e Representative histological images of early degenerated
canine NP injected with NaCl (d) or a 770 μM celecoxib (CXB)-loaded pNIPAAM MgFe hydrogel (e) stained with a COX-2 antibody and
counterstained with hematoxylin. No significant differences were found between the injected treatments. Chondrocyte-like cell (asterisk) density is
increased, and small size clones are present (arrow), indicative of early IVD degeneration. None of the cells in these NPs demonstrated positive
staining for the COX-2 antibody. Treatments: NaCl = NaCl (sham); CXB 7.7 μM = celecoxib bolus; CR = unloaded pNIPAAM MgFe-LDH hydrogel;
CR + CXB 7.7 μM = pNIPAAM MgFe-LDH hydrogel loaded with 7.7 μM CXB). *Indicates significant difference at a 99 % confidence level. ACAN
aggrecan, ADAMTS5 a disintegrin and metalloproteinase with thrombospondin motifs 5, BCL2 B-cell lymphoma 2, COL1A1 collagen type 1
alpha 1, COL2A1 collagen type 2 alpha 1, COX cyclooxygenase, IVD intervertebral disc, pNIPAAM poly-N-isopropylacrylamide
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To the authors’ knowledge this is the first study that de-
scribes biocompatibility and safe intradiscal application
of a thermoreversible pNIPAAM MgFe-LDH hydrogel
in vivo. The hydrogel was successfully employed as a ve-
hicle for the delivery of a COX-2 inhibitor into the IVD.
The selective COX-2 inhibitor celecoxib (CXB) was se-
lected, as this drug is commonly used to alleviate pain
symptoms associated with degenerative IVD conditions.
In vitro controlled release of CXB results into sustained
suppression of PGE2 levels associated with inflammation
In vitro, degradation behavior of the thermoresponsive
hydrogel was comparable for different loading dosages
of CXB. Although an increase in the cumulative release
of CXB as a percentage of the total amount loaded was
detected in gels with a lower loading dose, the absolute
amounts measured in the medium were comparable, dem-
onstrating a CXB solubility-dependent release. Hydrogelswith higher amounts of LDH particles showed a lower cu-
mulative Mg release, most likely due to an increase in an-
ionic exchange with the medium [40]. Neither an increase
in the amount of LDH particles, nor changes in the charge
of Mg affected the CXB release profiles. In vitro, stimula-
tion of three-dimensional chondrocyte constructs with 10
ng/ml TNF-α, resulted in increased PGE2 levels in the cul-
ture medium. Furthermore, in this in vitro model, we
confirmed the controlled release of CXB into the
medium from 0.1 mg/ml and 1 mg/ml CXB-loaded hydro-
gels, respectively. Unfortunately, CXB values measured by
the UPLC method showed high variances most probably
due to fact that the values were measured in the lower re-
gion of the UPLC detection method [23]. TNF-α-induced
PGE2 production was completely inhibited by 1 mg/ml
CXB-loaded pNIPAAM MgFe-LDH hydrogels, thereby
proving the efficacy of the CXB controlled release system to
suppress in vitro PGE2 production for a prolonged period in
contrast to the short-lived effect of a bolus of CXB.
Fig. 6 Representative macroscopic and histopathologic image stained
with alcian blue/picrosirius red of an IVD treated with NaCl (a) and
GAG and PGE2 levels normalized for DNA in nucleus pulposus (NP)
and annulus fibrosus (AF) tissue (b-c). The NP in figure (a) has a
bulging aspect due to the processing method. b GAG/DNA levels
were significantly higher in the NP than in the AF in all treatments.
c In all treatments PGE2/DNA levels were significantly lower in the
NP than those in the AF. Data are expressed as mean values ± standard
deviation. Treatments: NaCl = NaCl (sham); CXB 7.7 μM = celecoxib
bolus; CR = unloaded pNIPAAM MgFe-LDH hydrogel; CR + CXB
7.7 μM = pNIPAAM MgFe-LDH hydrogel loaded with 7.7 μM CXB;
CR + 77 μM = pNIPAAM MgFe-LDH hydrogel loaded with 77 μM
CXB; CR + CXB 770 μM = pNIPAAM MgFe-LDH hydrogel loaded
with 770 μM CXB). *Indicates significant difference at a 99 % confidence
level. CXB celecoxib, GAG glycosaminoglycan, IVD intervertebral
disc, LDH layered double hydroxide, PGE2 prostaglandin E2, pNIPAAM
poly-N-isopropylacrylamide
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thermoreversible pNIPAAM MgFe-LDH hydrogel
In vivo, subcutaneous injection of the hydrogel did not re-
sult in local or systemic adverse effects; histology showeda moderately irritant reaction with a shift from a pyogra-
nulomatous reaction into a granulomatous reaction with
formation of a fibrous capsule, consistent with a foreign
body reaction to biomaterials [41]. Based on these clinical
and histological findings, in combination with the avas-
cular nature of the IVD [42, 43], we concluded that the
hydrogel would be well tolerated when applied intradis-
cally. Indeed, safe intradiscal injection of thermorespon-
sive CXB-loaded and unloaded pNIPAAM MgFe-LDH
hydrogels was demonstrated in a large animal model, i.e.,
chondrodystrophic dogs, with naturally occurring IVD
degeneration. This was corroborated by IVD histology,
further determination of the anabolic/catabolic state of
the ECM and cell viability by means of gene expression
and biochemical analyses. The presence of the hydrogel
in the NP, in contrast to the subcutaneous location, was
not accompanied by a foreign body reaction. Histological
findings in the majority of the canine IVDs were unre-
markable. Notably, in one IVD injected with unloaded
hydrogel, fibrous tissue in the AF was detected, whereas
in another one, irregular EPs and clustering of chondro-
cytes in the dorsal AF were present. In one of the IVDs
injected with NaCl, acellular material and bulging of the
ventral AF were noted. These irregularities cannot be
attributed with certainty to the injections [18], and may
also reflect spontaneous progression of IVD degener-
ation. This study was conducted in mildly degenerated
IVDs without fissures in the AF and we demonstrated
safe intradiscal injection of 30 μl hydrogel through a
29G needle. However, we did not study the ability of
the pNIPAAM MgFe-LDH hydrogel to form an inter-
face with NP tissue and therefore we cannot exclude
the risk of extrusion of the biomaterial in severely
degenerated IVDs that contain annular fissures.
Viability of the resident NP cells of the NP was not
affected by the in vivo intradiscal application of the
pNIPAAM MgFe-LDH hydrogel loaded with CXB over
a wide dose range. Relative gene expression levels of the
anti-apoptotic gene BCL2 were significantly downregulated
in the NPs of IVDs injected with the CXB-loaded hydrogel
compared with the NaCl-injected IVDs. In numerous can-
cer cell lines overexpressing COX-2, CXB has been shown
to activate the intrinsic apoptotic pathway [44, 45]. How-
ever, in our study, gene expression levels of other apoptotic
markers, i.e., CAV1, CASP3, and FasL, together with results
of the TUNEL assay showed no evidence that apoptosis
was affected by the intradiscal application of (un)loaded
pNIPAAM MgFe-LDH hydrogel in vivo. Altogether this
indicates that the differences of BCL2 on gene expres-
sion level may not be of biological relevance. In line with
the aforementioned, expression levels for notochordal cell
markers T, CK8 and CK18 did not differ between groups
indicating that neither the injection nor the (un)loaded
biomaterial had an adverse effect on IVD health.
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pNIPAAM MgFe-LDH hydrogel loaded with a wide range
of CXB dosages
The pNIPAAM MgFe-LDH hydrogel loaded with CXB
over a wide dose range also appeared to be biocompatible
and safe for intradiscal application at a biomolecular and
biochemical level. Intradiscal injection was not associated
with IVD herniation, or with progression of degener-
ation. Overall, there were no significant differences be-
tween treatments on expression levels of other catabolic
(MMP13) and anti-catabolic (TIMP1) genes, genes of extra-
cellular matrix (ECM) components, i.e., ACAN, COL2A1,
COL1A1, and the GAG/DNA content. Furthermore, gene
expression levels of ADAMTS5 were significantly upregu-
lated in NPs treated with the CXB bolus and the CXB-
loaded hydrogel, independent of the dose, compared with
NPs treated with the unloaded hydrogel, suggestive of a
catabolic effect of CXB. In line with this, ADAMTS5 gene
expression levels did not significantly differ between IVDs
injected with unloaded hydrogels and NaCl. Our findings
do not correspond with upregulated levels of ADAMTS4
reported in bovine NPCs cultured in hyaluronan-based
(HA)-pNIPAAM hydrogels compared with NPCs cultured
in alginate beads. Nevertheless, these results should be
compared to our results with care, as the relevant fold-
change in gene expression was limited to a twofold dif-
ference in our study, and the experimental environment
(i.e., in vitro versus in vivo), as well as the tissue and
the composition of the hydrogel differed [46]. Altogether,
the pNIPAAM MgFe-LDH hydrogel is biocompatible
and can be safely injected in the IVD without affecting
the IVD health based on the overall results of histological
scores, immunohistochemical indices, gene expression
profiles, and biochemical analyses.
Controlled release of CXB in mildly degenerated IVDs had
a limited effect on PGE2 levels
Over the period of 28 days and there was no dose-
dependent effect in a wide range of CXB concentrations.
Due to technical limitations we were not able to determine
the CXB tissue levels in vivo and hence cannot elaborate
on the in vivo release profile of the loaded hydrogels specif-
ically in the matrix-rich NP environment. As CXB has a
relatively high protein-binding capacity, the protein-rich
NP might have enhanced CXB solubility, hence an in-
creased release of CXB from the hydrogel [47]. Given that
the only available reports on the effect of CXB on PGE2
production by IVD cells are from in vitro experiments,
the discussion of the results is further limited by differ-
ences between cell responses in an in vivo and an
in vitro situation. Furthermore, PGE2 levels detected in
these in vitro experiments are expressed in PGE2/ml
medium or PGE2/total protein, and in none of them in
PGE2/DNA [6, 7, 9, 10, 48]. When correcting the PGE2levels for protein content in the NP (Additional file 4),
the results are consistent with findings in 7-day cultures
of human grade 3 degenerated tissue, which showed no
inhibition of PGE2 production in the presence of 1 μM
CXB [48]. Although we cannot rule out a suboptimal
effect of the CXB-loaded hydrogels in the intradiscal envir-
onment, the lack of PGE2 inhibition by CXB in the current
study may have been attributable to the constitutive activ-
ity of COX-1 and the absence of inflammation-induced
COX-2 activity. The low percentage of COX-2-positive
cells detected at the immunohistochemical level supports
this theory. Furthermore, in patients with degenerative
joint cartilage, treatment with CXB for a period of 28
days has been shown to have a beneficial effect on GAG
turnover, mainly due to COX-2 inhibition. GAG/DNA
was not significantly different for any of the treatments,
which may also be associated with the absence of COX-2
activity in this model. Insufficient statistical power because
of the modest sample size (N = 18) may have played a role
in limiting the significance of the statistical comparisons
conducted (Additional file 3).
Although MR images, macroscopic, and histologic find-
ings were consistent with mild degeneration, this phase in
the degenerative cascade may actually not be associated
with increased PGE2 levels, suggesting that inflammation
occurs at a later time point, i.e., when disc protrusion
and/or clinical signs are present. Incorporation of general
COX inhibitors into the hydrogel may provide clarity on
this.
Interestingly, regardless of the treatment condition,
PGE2/DNA levels measured in the AF in our study were
significantly higher than the levels detected in the NP
for all conditions, while GAG/DNA levels in the AF were
significantly lower than levels in the NP, in accordance
with previous studies [5, 20]. In contrast, Miyamoto et al.
described similar PGE2/ml levels in control NP and AF
cell cultures, but showed a higher production of PGE2 by
AF cells compared with NP cells in response to a cyclic
mechanical load [49].
Inflammation is thought to play an important role in
the process of IVD degeneration and disease [25]. Ad-
dressing the origin of inflammatory responses and hence
an earlier stage of the degenerative cascade, may be more
successful in suppressing inflammation and restoring IVD
homeostasis. Emerging treatment strategies aiming at con-
trolled release of anti-inflammatory medication that target
proinflammatory mediators, e.g., TNF-α and PGE2 levels
in the IVD, will need to focus on IVDs in human and/or
veterinary patients with clinical signs of IVD disease
[16, 25, 50]. PGE2 levels elevated in the course of a true
inflammatory response in NP and/or AF tissue may be
effectively decreased by selective COX-2 inhibitors, such
as CXB. However, CXB release and bioavailability in the
intradiscal environment should be understood in more
Willems et al. Arthritis Research & Therapy  (2015) 17:214 Page 15 of 16detail. If these issues are solved, pNIPAAM MgFe-LDH
hydrogels loaded with CXB might be a promising long-
term treatment in patients with herniated discs and
chronic low back pain that can be minimally invasive
injected into the diseased IVD assisted by fluoroscopy
or computer tomography.
Conclusions
We have demonstrated the biocompatibility and safety
of a pNIPAAM MgFe-LDH hydrogel via subcutaneous
application in mice and via intradiscal administration in
a large animal model. Furthermore, we have shown its
capability for controlled delivery of the anti-inflammatory
drug CXB, resulting in suppressed PGE2 levels in a TNF-
α-stimulated three-dimensional tissue-engineered model
system for up to 28 days. The controlled release of CXB
from this hydrogel resulted in limited inhibition of PGE2
production in a large animal model with spontaneous IVD
degeneration. This may be due to the stage of degener-
ation rather than the efficacy of the controlled release
system.
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